ELIGARD PACKAGE INSERT PDF

Discard both caps. Be careful not to over tighten. Thoroughly mix the product by pushing back and forth between the syringes for about 45 seconds to obtain a uniform suspension. NOTE: Product must be mixed as described to ensure a uniform suspension is achieved. Shaking will not provide adequate mixing of the product.

Author:Mikalmaran Mezigrel
Country:Poland
Language:English (Spanish)
Genre:Medical
Published (Last):13 September 2005
Pages:267
PDF File Size:13.16 Mb
ePub File Size:4.46 Mb
ISBN:711-7-91333-296-4
Downloads:77639
Price:Free* [*Free Regsitration Required]
Uploader:Shaktim



Goltikinos Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include mefloquine. Major Avoid coadministration of leuprolide with toremifene if possible due to the risk of additive QT prolongation. For the monthly 3.

Major Periodically monitor electrolytes and ECGs in patients receiving concomitant treatment with ceritinib and leuprolide; an interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation occurs.

Drugs with a possible packagge for QT prolongation that should be used cautiously and with close monitoring with citalopram include leuprolide. Major Avoid coadministration of lenvatinib with leuprolide due to the risk of QT prolongation.

Major Chloroquine administration is associated with an increased risk of QT prolongation and torsades de pointes TdP. Children 2 to 11 years. Major Avoid coadministration of leuprolide with osimertinib if possible due to the risk of QT prolongation and torsade de pointes TdP. According packagee the manufacturer of asenapine, the drug should be avoided in combination with other agents also known to have this effect. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be avoided in combination with asenapine include leuprolide.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with clarithromycin include leuprolide. Normally, GnRH is released in a pulsatile fashion, but the sustained activity of leuprolide leads to downregulation of the receptor and decreased production of follicle-stimulating hormone FSH and luteinizing hormone LH.

Prolongation of the QT interval has been reported with lenvatinib therapy. Halofantrine should be avoided in patients receiving drugs which may induce QT prolongation. Moderate Androgen-deprivation ineert e. Your email has been sent. Lithium has been associated with QT prolongation.

Major Avoid coadministration of hydroxychloroquine and leuprolide. Patients receiving other drugs which have the potential for QT prolongation have an increased paxkage of developing proarrhythmias during bepridil therapy. Drugs sligard a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include telithromycin. The increase in QTc is approximately 10 milliseconds at doses of mg twice daily the FDA-approved dose and up to 25 milliseconds at doses of mg twice daily.

Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. If these agents are used together, obtain an ECG and serum electrolytes prior to the start of gemtuzumab and as needed during treatment. Brain tumor, cerebrovascular disease, seizure disorder. Leuprolide inesrt interrupts menstruation; women who continue to cycle or who experience breakthrough bleeding while receiving leuprolide should notify their physician.

Because of the potential for TdP, use of sparfloxacin with leuprolide is contraindicated. Androgen deprevation therapy, such as leuprolide, may cause QT prolongation. Drugs with a possible risk for QT prolongation and Eligqrd that should be used cautiously and with close monitoring with leuprolide include fluconazole.

Oops Something Went Wrong! Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include trazodone.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with leuprolide include atomoxetine. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of torsade de pointes TdP in patients with multiple confounding factors.

Additionally, antipsychotic-induced hyperprolactinemia results in down-regulatation of the number of pituitary GnRH receptors and may interfere with the response to leuprolide therapy; however, in contrast to most typical antipsychotics, clozapine is not often associated with hyperprolactinemia.

If vemurafenib and another drug associated with a possible risk for QT prolongation and torsade de pointes TdP must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation. At this time, there are no known comparable studies evaluating the risk of cardiovascular events in women or children taking GnRH agonists for other indications. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with leuprolide include vorinostat.

Major The administration of lumefantrine is associated with prolongation of the QT interval. Because of the potential for TdP, use of halofantrine with leuprolide is contraindicated. For patients who are self-administering leuprolide injection, make sure they are using the syringes provided by the manufacturer.

Hold syringe B upright. Excessive doses particularly in the overdose setting or IV administration of haloperidol may be associated with a higher risk of QT prolongation. Do not use partial syringes or a combination of syringes to achieve a particular dose or to titrate dosages.

Eligard leuprolide acetate dose, indications, adverse effects, interactions from Drugs with a possible risk for QT prolongation and TdP that should be used cautiously with leuprolide include mifepristone. The manufacturer warns that the QT effect of alfuzosin should be considered prior to administering the drug to patients taking other medications known to prolong the QT interval. Moderate Monitor ECG if lofexidine is coadministered with leuprolide due ihsert the potential for additive QT prolongation.

Keep the syringe upright. Major Avoid the concomitant use of nilotinib and leuprolide acetate; significant prolongation of the QT interval may occur. In clinical trials, patients receiving this dosage ranged from The co-administration of panobinostat with leuprolide is not recommended; QT prolongation has been reported with both agents.

TOP Related.

DVIOUT WINDOWS PDF

PROSTATE CANCER

If you have any questions, please ask your doctor. Doctors may diagnose children with CPP when signs of sexual maturity begin to develop in girls under the age of 8 or boys under the age of 9. Your doctor should perform tests to rule out possible causes of early puberty that would require different treatment e. Seizures have also been reported in patients without any of these conditions. You should notify your doctor if you experience fluid retention, seizure, asthma or worsening of asthmatic symptoms, or heart or kidney problems. Since some conditions may increase the possibility of bone thinning, you should tell your doctor if you smoke, use alcohol in excess, have a family history of osteoporosis thinning of the bones with fractures , or are taking other medications that can cause thinning of the bones.

D-LINK 2640B MANUAL PDF

Leuprorelin

Goltikinos Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with leuprolide include mefloquine. Major Avoid coadministration of leuprolide with toremifene if possible due to the risk of additive QT prolongation. For the monthly 3. Major Periodically monitor electrolytes and ECGs in patients receiving concomitant treatment with ceritinib and leuprolide; an interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation occurs. Drugs with a possible packagge for QT prolongation that should be used cautiously and with close monitoring with citalopram include leuprolide.

PANASONIC DMR EH69 PDF

ELIGARD is given via subcutaneous injection (just under the skin)

Kajiramar Major Chloroquine administration is associated with an increased risk of QT prolongation and torsades de pointes Onsert. Coadministration with other QT prolonging drugs may result in additive or synergistic prolongation of the QT interval; avoid such agents if possible. ECG monitoring is recommended during use. In clinical trials, patients receiving the 7. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be used cautiously and with close monitoring with bedaquiline include leuprolide.

Related Articles